Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), step decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), step decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
1701
Data for Figs 8A–8H, 9A–9K, 10A–10I.
Published 2024“…In <i>vivo</i> experiments further showed that PRV UL4 (<sup>132</sup>DVAADAAAEAAAAE<sup>145</sup>) mutated strain (PRV-UL4<sup>mut</sup>) infection did not lead to a significant decrease in viral titers at 12 h. p. i, but it induced lower levels of IL-1β, IL-18, and GSDMD-NT, which led to an alleviated inflammatory infiltration and pathological damage in the lungs and brains, and a lower death rate compared with wild-type PRV strain infection. …”
-
1702
Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg
Published 2025“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
-
1703
Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg
Published 2025“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
-
1704
Store listing metrics and user acquisition.
Published 2025“…Interrupted time series analyses found gradual adoption and sustained retention following intervention start, but significant decrease at campaign end.</p><p>Conclusion</p><p>A context‑adapted, multi‑channel marketing strategy markedly improved adoption and retention of the WHO SkinNTDs app among Cameroonian FHWs. …”
-
1705
Installation, growth, and retention metrics.
Published 2025“…Interrupted time series analyses found gradual adoption and sustained retention following intervention start, but significant decrease at campaign end.</p><p>Conclusion</p><p>A context‑adapted, multi‑channel marketing strategy markedly improved adoption and retention of the WHO SkinNTDs app among Cameroonian FHWs. …”
-
1706
Implemented activities.
Published 2025“…Interrupted time series analyses found gradual adoption and sustained retention following intervention start, but significant decrease at campaign end.</p><p>Conclusion</p><p>A context‑adapted, multi‑channel marketing strategy markedly improved adoption and retention of the WHO SkinNTDs app among Cameroonian FHWs. …”
-
1707
App user retention trends.
Published 2025“…Interrupted time series analyses found gradual adoption and sustained retention following intervention start, but significant decrease at campaign end.</p><p>Conclusion</p><p>A context‑adapted, multi‑channel marketing strategy markedly improved adoption and retention of the WHO SkinNTDs app among Cameroonian FHWs. …”
-
1708
App user onboarding trends.
Published 2025“…Interrupted time series analyses found gradual adoption and sustained retention following intervention start, but significant decrease at campaign end.</p><p>Conclusion</p><p>A context‑adapted, multi‑channel marketing strategy markedly improved adoption and retention of the WHO SkinNTDs app among Cameroonian FHWs. …”
-
1709
App user base growth trends.
Published 2025“…Interrupted time series analyses found gradual adoption and sustained retention following intervention start, but significant decrease at campaign end.</p><p>Conclusion</p><p>A context‑adapted, multi‑channel marketing strategy markedly improved adoption and retention of the WHO SkinNTDs app among Cameroonian FHWs. …”
-
1710
-
1711
<i>SLC2A2</i> is essential for liver differentiation in developing vertebrates
Published 2025“…Data are represented as mean ± standard error of the mean (SEM). (G) Quantitative RT-PCR analysis was performed to evaluate the expression levels of igf1r. …”
-
1712
DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF
Published 2024“…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”
-
1713
DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF
Published 2024“…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”
-
1714
DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF
Published 2024“…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”
-
1715
DataSheet4_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF
Published 2024“…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”
-
1716
Primer sequences for RT-qPCR.
Published 2025“…Data from TCGA showed that NCOA4 shows greater downgrade in tumor tissues than in non-tumor tissues and the overall survival (OS) of patients with low NCOA4 expression was significantly shorter than that of patients with high NCOA4 expression.The qPCR results showed that NCOA4 was expressed at low levels in cholangiocarcinoma tissue specimens; the mRNA expression of NCOA4 decreased after knocking down NCOA4 in cells. …”
-
1717
siRNA sequences and negative controls sequences.
Published 2025“…Data from TCGA showed that NCOA4 shows greater downgrade in tumor tissues than in non-tumor tissues and the overall survival (OS) of patients with low NCOA4 expression was significantly shorter than that of patients with high NCOA4 expression.The qPCR results showed that NCOA4 was expressed at low levels in cholangiocarcinoma tissue specimens; the mRNA expression of NCOA4 decreased after knocking down NCOA4 in cells. …”
-
1718
Antibodies used in the study.
Published 2025“…Data from TCGA showed that NCOA4 shows greater downgrade in tumor tissues than in non-tumor tissues and the overall survival (OS) of patients with low NCOA4 expression was significantly shorter than that of patients with high NCOA4 expression.The qPCR results showed that NCOA4 was expressed at low levels in cholangiocarcinoma tissue specimens; the mRNA expression of NCOA4 decreased after knocking down NCOA4 in cells. …”
-
1719
-
1720
Differences in mean scores of upper extremity performance in all five accelerometer-derived variables across four time points- pre-HABIT, post-HABIT, 3-month, and 6-month post-HABI...
Published 2024“…<p>Values reported are means ± SEM as determined by distribution of data during each assessment time point. …”